Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 37 |
| Active Pipeline (Recruiting Now) | 21 (11) |
| Completed vs Stopped Early | 13 / 0 (0.0%) |
| Median Closed Actual Enrollment | 218 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Shanghai Chest Hospital | Shanghai | 2 |
| Nanjing Drum Tower Hospital | Nanjing | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05881837 | A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes | Phase II | COMPLETED |
Explore interactive annual charts and M&A subsidiary rollups in the Fujian Shengdi Pharmaceutical Co Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.